Get help for your patients with XIPERE savings and support

Your source of support for accessing XIPERE

Focus on Access (FOA) offers support services to help ensure your patients receive XIPERE™ just as you prescribed.

Getting started is easy, either call 1-866-272-8838 or complete the registration form to get underway.

Get Started

Focus on Access

1-866-272-8838

Monday – Friday, 9:00 AM to 5:00 PM ET

Focus on Access offers:

  • Personal FOA Access Case Coordinator who can share information about insurance coverage
  • Rapid benefits investigation and verification
  • Prior authorization and process support
  • PA appeals and claims information
  • Billing and coding resources
  • Copay support for eligible, commercially insured patients
  • Financial assistance referrals for eligible patients*

*Terms and conditions apply and can be found on the FOA enrollment form. Please be sure to share eligibility criteria with your patients. Bausch + Lomb does not guarantee coverage or reimbursement for the product.

  • Personal FOA Access Case Coordinator who can share information about insurance coverage
  • Rapid benefits investigation and verification
  • Prior authorization and process support
  • PA appeals and claims information
  • Billing and coding resources
  • Copay support for eligible, commercially insured patients
  • Financial assistance referrals for eligible patients*

*Terms and conditions apply and can be found on the FOA enrollment form. Please be sure to share eligibility criteria with your patients. Bausch + Lomb does not guarantee coverage or reimbursement for the product.

Additional resources you may need to start patients on XIPERE

There is a comprehensive suite of offerings available to help support your patients.

Click below to download the form you need.

Coming Soon: Order XIPERE

Answers to common questions about XIPERE and the SCS Microinjector®

XIPERE treats macular edema (ME) associated with all anatomical locations of uveitis.1

XIPERE is the only treatment approved to deliver medicine via the suprachoroidal space and the first and only uveitic macular edema treatment to demonstrate clinical efficacy with a BCVA primary endpoint.1

The primary endpoint was the number of patients who achieved significant BCVA improvements of 15 or more letters from baseline at 24 weeks.

XIPERE is contraindicated in patients with active or suspected ocular or periocular infections including most viral diseases of the cornea and conjunctiva, for example1:

  • active epithelial herpes simplex keratitis (dendritic keratitis)
  • vaccinia
  • varicella
  • mycobacterial infections
  • fungal diseases

XIPERE is also contraindicated in patients with known hypersensitivity to triamcinolone acetonide or any other components of this product.

The most common ocular adverse reactions ranged from nonacute elevated IOP (patients treated with XIPERE and patients in the control group were equivalent at a rate of 14%, n=13/96 and n=9/64 respectively) to blurred vision at 2% of patients treated with XIPERE with zero reports in the control group (n=2/96 and n=0/64 respectively).

Please see full adverse events profile under Safety & Tolerability section.

The SCS Microinjector® is composed of a syringe and two 30-gauge hollow microneedles of 900 μm and 1100 μm in free length.1

This suprachoroidal injection is designed to be carried out perpendicular to the sclera under local anesthesia. Once the microneedle penetrates the sclera and reaches the SCS®, the open bevel of the needle releases the drug which spreads to the back of the eye, targeting the tissues of interest.1,2

Yes. Training is highly recommended for the administering specialist.

You can schedule a training session by sharing your name and email address and a local representative will be in touch to arrange.

 

Indication

XIPERE (triamcinolone acetonide injectable suspension) for suprachoroidal use is a corticosteroid indicated for the treatment of macular edema associated with uveitis.

Important Safety Information

Patients should be monitored following injection for elevated intraocular pressure. See Dosage and Administration instructions in full Prescribing Information.

  • XIPERE is contraindicated in patients with active or suspected ocular or periocular infections including most viral diseases of the cornea and conjunctiva, including active epithelial herpes simplex keratitis (dendritic keratitis), vaccinia, varicella, mycobacterial infections, and fungal diseases.
  • XIPERE is contraindicated in patients with known hypersensitivity to triamcinolone acetonide or any other components of this product.
  • Use of corticosteroids may produce cataracts, increased intraocular pressure, and glaucoma. Use of corticosteroids may enhance the establishment of secondary ocular infections due to bacteria, fungi, or viruses, and should be used cautiously in patients with a history of ocular herpes simplex.
  • Hypothalamic-pituitary-adrenal (HPA) axis suppression, Cushing’s syndrome, and hyperglycemia can occur following administration of a corticosteroid. Monitor patients for these conditions with chronic use.
  • In controlled studies, the most common ocular adverse reactions were increased ocular pressure, non-acute (14%), eye pain, non-acute (12%), cataract (7%); increased intraocular pressure, acute (6%), cataract (7%), vitreous detachment (5%), injection site pain (4%) conjunctival hemorrhage (4%), visual acuity reduced (4%), dry eye (3%), eye pain, acute (3%), photophobia (3%), and vitreous floaters (3%), and in 2% of patients: uveitis, conjunctival hyperaemia, punctate keratitis, conjunctival oedema, meibomianitis, anterior capsule contraction, chalazion, eye irritation, eye pruritus, eyelid ptosis, photopsia, and vision blurred.
    The most common non-ocular adverse event was headache (5%).
  • Corticosteroids should be used during pregnancy or nursing only if the potential benefit justifies the potential risk to the fetus or nursing infant.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088.

Please click here for full Prescribing Information.

References

  1. XIPERE [prescribing information]. Alpharetta, GA: Clearside Biomedical, Inc.; 2021.
  2. Yeh S, Khurana RN, Shah M, et al. Efficacy and safety of suprachoroidal CLS-TA for macular edema secondary to noninfectious uveitis: phase 3 randomized trial. Ophthalmology. 2020;127(7):948-955.
  3. Rai Udo J, Young SA, Thrimawithana TR, et al. The suprachoroidal pathway: a new drug delivery route to the back of the eye. Drug Discov Today. 2015;20(4):491-495.

Indication

Important Safety Information

XIPERE (triamcinolone acetonide injectable suspension) for suprachoroidal use is a corticosteroid indicated for the treatment of macular edema associated with uveitis.

Important Safety Information

Patients should be monitored following injection for elevated intraocular pressure. See Dosage and Administration instructions in full Prescribing Information.

  • XIPERE is contraindicated in patients with active or suspected ocular or periocular infections including most viral diseases of the cornea and conjunctiva, including active epithelial herpes simplex keratitis (dendritic keratitis), vaccinia, varicella, mycobacterial infections, and fungal diseases.

Patients should be monitored following injection for elevated intraocular pressure. See Dosage and Administration instructions in full Prescribing Information.